SAUDI-ECONOMY-PLANNING
29.4.2024 23:03:34 CEST | Business Wire | Press release
Riyadh hosted more than 1,000 global leaders for the two-day World Economic Forum (WEF) Special Meeting in Riyadh, where leading political, economics, energy and technology figures called for clear pathways to stability, prosperity and inclusive growth opportunities in the face of rising cross-border challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429767765/en/
Saudi Minister of Economy and Planning His Excellency Faisal Alibrahim announces Saudi Arabia will join the AI Governance Alliance to co-launch the ‘Inclusive AI Initiative for Growth and Development’ (Photo: AETOSWire)
The more than 1,000 participants in for the WEF Special Meeting on Global Collaboration, Growth and Energy for Development made it the highest-ever number of registrations for a WEF event hosted outside of its Annual Meeting venue in Davos Klosters, Switzerland.
The Special Meeting set the stage for the launch of several initiatives in the fields of healthcare, artificial intelligence, space and sustainability. On the final day of the meeting, chief executive officer of Moderna, Stéphane Bancel, said the American pharmaceutical company is working to have the first product for cancer on the healthcare market, potentially as early as 2025.
On the first day of the meeting, the Saudi Ministry of Health signed a memorandum of understanding with the Bill & Melinda Gates Foundation to ensure equitable access to healthcare services for all, and to deliver more vaccines against polio, measles, and other vital health services to millions of children worldwide. It was one of several agreements signed by the Foundation with the Kingdom to improve global health systems and access.
During the final plenary session, Saudi Arabia’s Minister of Economy and Planning His Excellency Faisal Alibrahim announced that the Kingdom joined the AI Governance Alliance, and will co-launch the ‘Inclusive AI Initiative for Growth and Development’, to develop solutions for AI access and adoption.
The Saudi Space Agency also announced that it will launch the Center for Space Futures in the Kingdom later this year, in collaboration with WEF. The Center will serve as a platform for public-private dialogues and foster the growth of the global space economy.
A Saudi Arabia-led Sustainability Champions Network was also launched on the sidelines of the Special Meeting to accelerate Saudi’s private sector decarbonization efforts.
Saudi Arabia also announced an extension to its collaboration with WEF’s innovation platform UpLink, with two new initiatives that focus on developing solutions to reducing emissions through the circular carbon economy and regenerating the world’s oceans through blue economy innovations.
WEF President Børge Brende hailed the Special Meeting in Riyadh a consequential gathering that drew the attendance of key global leaders including the President of Palestine, Mahmoud Abbas; United States Secretary of State, Anthony Blinken; the United Kingdom’s Foreign Secretary, David Cameron.
Leading philanthropist Bill Gates joined a session on “Bridging the Health Gap”, alongside Dr. Tedros Adhanom Ghebreyesus Director-General, World Health Organization (WHO), and Fahad bin Abdurrahman Al-Jalajel, Minister of Health, Ministry of Health of Saudi Arabia.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429767765/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom